Importance of the association between Kikuchi disease and Systemic Lupus Erythematosus
DOI:
https://doi.org/10.32818/reccmi.a7n1a4Keywords:
systemic lupus erythematosus, Kikuchi’s disease, necrotizing histiocytic lymphadenopathy, adenopathy, lupus nephropathyAbstract
Necrotizing histiocytic lymphadenopathy or Kikuchi's Disease (KD) is a rare clinical entity that is occasionally associated with systemic lupus erythematosus (SLE). The histologic features of the disorder have been considered indistinguishable to lymphadenitis in patients with SLE, and the clinical symptoms of the two disorders share common features. This article presents a clinical case of a 23-year-old woman with a history of KD who later developed SLE.
Downloads
Metrics
References
Kuo TT. Kikuchi's disease (histiocytic necrotizing lymphadenitis). A clinicopathologic study of 79 cases with an analysis of histologic subtypes, immunohistology, and DNA ploidy. Am J Surg Pathol. 1995; 19(7): 798-809. doi: https://doi.org/10.1097/00000478-199507000-00008.
Dumas G, Prendki V, Haroche J, Amoura Z, Cacoub P, Galicier L, et al. Kikuchi-Fujimoto Disease. Medicine (Baltimore). 2014; 93(24): 372-82. doi: https://doi.org/10.1097/MD.0000000000000220.
Kojima M, Motoori T, Asano S, Nakamura S. Histological diversity of reactive and atypical proliferative lymph node lesions in systemic lupus erythematosus patients. Pathol Res Pract. 2007; 203(6): 423-31. doi: https://doi.org/10.1016/j.prp.2007.03.002.
Huang J, Zheng JX, Yang Y, Zhu D. Necrotizing lymphadenitis: A case report and literature review. Z Rheumatol. 2021; 80(3): 274-282. doi: https://doi.org/10.1007/s00393-020-00929-6.
Sopeña B, Rivera A, Chamorro A, Freire M, Alende V, Seco E, et al. Clinical association between Kikuchi׳s disease and systemic lupus erythematosus: A systematic literature review. Semin Arthritis Rheum. 2017; 47(1): 46-52. doi: https://doi.org/10.1016/j.semarthrit.2017.01.011.
Kim SK, Kang MS, Yoon BY, Kim DY, Cho SK, Bae SC, et al. Histiocytic necrotizing lymphadenitis in the context of systemic lupus erythematosus (SLE): Is histiocytic necrotizing lymphadenitis in SLE associated with skin lesions? Lupus. 2011; 20(8): 809-19. doi: https://doi.org/10.1177/0961203310397684.
Honda F, Tsuboi H, Toko H, Ohyama A, Takahashi H, Abe S, et al. Recurrent Kikuchi-Fujimoto Disease Successfully Treated by the Concomitant Use of Hydroxychloroquine and Corticosteroids. Intern Med. 2017; 56(24): 3373-3377. doi: https://doi.org/10.2169/internalmedicine.9205-17.
Chen Y, Sun J, Zou K, Yang Y, Liu G. Treatment for lupus nephritis: an overview of systematic reviews and meta-analyses. Rheumatol Int. 2017; 37(7): 1089-1099. doi: https://doi.org/10.1007/s00296-017-3733-2.
Müller CSL, Vogt T, Becker SL. Kikuchi-Fujimoto Disease Triggered by Systemic Lupus Erythematosus and Mycoplasma pneumoniae Infection-A Report of a Case and a Review of the Literature. Am J Dermatopathol. 2021; 43(3): 202-208. doi: https://doi.org/10.1097/DAD.0000000000001764.
Racette SD, Alexiev BA, Angarone MP, Bhasin A, Lima K, Jennings LJ, et al. Kikuchi-Fujimoto disease presenting in a patient with SARS-CoV-2: a case report. BMC Infect Dis. 2021; 21(1): 740. doi: https://doi.org/10.1186/s12879-021-06048-0.
Stimson L, Stitson R, Bahhadi-Hardo M, Renaudon-Smith E. COVID-19 associated Kikuchi-Fujimoto disease. Br J Haematol. 2021 Mar; 192(5):e124-e126. doi: https://doi.org/10.1111/bjh.17292.
Soub HA, Ibrahim W, Maslamani MA, A Ali G, Ummer W, Abu-Dayeh A. Kikuchi-Fujimoto disease following SARS CoV2 vaccination: Case report. IDCases. 2021; 25: e01253. doi: https://doi.org/10.1016/j.idcr.2021.e01253.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Sergio Carrasco-Molina, Jorge Álvarez-Troncoso, Ángel Robles-Marhuenda, Francisco Arnalich-Fernández
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
